Please login to the form below

Not currently logged in
Email:
Password:

Takeda appoints head of emerging markets

Takeda has named Jostein Davidsen as head of emerging markets following the pharmaceutical company's acquisition of Nycomed

Takeda has named Jostein Davidsen as head of emerging markets following the pharmaceutical company's acquisition of Nycomed, effective immediately.

Davidsen's new role is in addition to his current position as area head of Russia/CIS, and will see him lead Takeda in an area the company sees as key to achieving sustainable growth.

The region comprises Russia/CIS, Latin America, Middle East-Turkey-Africa, and South Asia.

Davidsen had been head of Nycomed Russia/CIS area since 1994, leading the company to its position among the top biggest-selling 10 companies in terms of sales in the area.

In 2010, Nycomed had total sales of €479m in Russia/CIS, achieving growth of 31 per cent in local currencies.

The company has also been involved with several partnership deals in the area and has invested in the development of a manufacturing plant in the Russian city of Yaroslavl.

Davidsen will report to Frank Morich, executive vice-president, International Operations (Americas/Europe), Takeda, and CEO of Nycomed.

17th October 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Sciterion

Sciterion is an award winning specialist healthcare communications consultancy within the Havas Health network of companies. We exist to make...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics